Ceftaroline fosamil for the empiric treatment of hospitalized adults with cSSTI: an economic analysis from the perspective of the Spanish National Health System

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Torres, Antoni
• dc.contributor.author Soriano, Alex
• dc.contributor.author Rivolo, Simone
• dc.contributor.author Remak, Edit
• dc.contributor.author Peral, Carmen
• dc.contributor.author Kantecki, Michal
• dc.contributor.author Ansari, Wajeeha
• dc.contributor.author Charbonneau, Claudie
• dc.contributor.author Hammond, Jennifer
• dc.contributor.author Grau Cerrato, Santiago
• dc.contributor.author Wilcox, Mark
• dc.date.accessioned 2022-10-20T06:58:35Z
• dc.date.available 2022-10-20T06:58:35Z
• dc.date.issued 2022
• dc.description.abstract Purpose: complicated skin and soft tissue infections (cSSTI) are associated with high healthcare resource use and costs. The emergency nature of cSSTI hospitalizations requires starting immediate empiric intravenous (IV) antibiotic treatment, making the appropriate choice of initial antibiotic therapy crucial. Patients and methods: the use of ceftaroline fosamil (CFT) as an alternative to other IV antibiotic therapies for the empiric treatment of hospitalized adults with cSSTI (vancomycin, linezolid, daptomycin, cloxacillin, tedizolid) was evaluated through cost consequences analysis. The model structure was a decision tree accounting for four different pathways: patients demonstrating early response (ER) either discharged early (with oral antibiotic) or remaining in hospital to continue the initial therapy; non-responders either remaining on the initial IV therapy or switching to a second-line antibiotic. The model perspective was the Spanish National Health System. Results: CFT resulted in average percentage of patients discharged early (PDE) of 24.6% (CI 19.49-30.2%) with average total cost per patient of €6763 (€6268-€7219). Vancomycin, linezolid, daptomycin and tedizolid resulted in average PDE of 22% (17.34-27.09%), 26.4% (20.5-32.32%), 28.6% (22.08-35.79%) and 26.5% (20.39-33.25%), respectively, for a total cost per patient of €6,619 (€5,902-€6,929), €6,394 (€5,881-€6,904), €6,855 (€5,800-€7,410) and €7,173 (€6,608-€7,763), respectively. Key model drivers were ER and antibiotic treatment duration, with hospital costs accounting for over 83% of the total expenditures. Conclusion: given its clinical and safety profile, CFT is an acceptable choice for cSSTI empiric therapy providing comparable ER and costs to other relevant antibiotic options.
• dc.format.mimetype application/pdf
• dc.identifier.citation Torres A, Soriano A, Rivolo S, Remak E, Peral C, Kantecki M et al. Ceftaroline fosamil for the empiric treatment of hospitalized adults with cSSTI: an economic analysis from the perspective of the Spanish National Health System. Clinicoecon Outcomes Res. 2022 Mar 18; 14: 149-61. DOI: 10.2147/CEOR.S329494
• dc.identifier.doi http://dx.doi.org/10.2147/CEOR.S329494
• dc.identifier.issn 1178-6981
• dc.identifier.uri http://hdl.handle.net/10230/54497
• dc.language.iso eng
• dc.publisher Dove Press
• dc.rights Copyright © 2022 Torres et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by-nc/3.0/
• dc.subject.keyword Spain
• dc.subject.keyword Ceftaroline fosamil
• dc.subject.keyword Complicated skin and soft tissue infection
• dc.subject.keyword Cost-consequences
• dc.title Ceftaroline fosamil for the empiric treatment of hospitalized adults with cSSTI: an economic analysis from the perspective of the Spanish National Health System
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion